Early View e202507702
Review

Unconventional PROTACs for Targeted Protein Degradation in Cancer Therapy

Xu Zhang

Xu Zhang

School of Life Sciences, Faculty of Medicine, Tianjin University, Tianjin, 300072 P.R. China

Search for more papers by this author
Zhangzhi Song

Zhangzhi Song

School of Life Sciences, Faculty of Medicine, Tianjin University, Tianjin, 300072 P.R. China

Search for more papers by this author
Xinyu Zhang

Xinyu Zhang

School of Life Sciences, Faculty of Medicine, Tianjin University, Tianjin, 300072 P.R. China

Search for more papers by this author
Jianhua Zou

Corresponding Author

Jianhua Zou

Department of Diagnostic Radiology, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, 119074 Singapore

Clinical Imaging Research Centre, Centre for Translational Medicine, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, 117599 Singapore

Nanomedicine Translational Research Program, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, 117597 Singapore

Theranostics Center of Excellence (TCE), Yong Loo Lin School of Medicine, National University of Singapore, Singapore, 138667 Singapore

E-mail: [email protected]; [email protected]; [email protected]; [email protected]

Search for more papers by this author
Guocan Yu

Corresponding Author

Guocan Yu

Ministry of Education Key Laboratory of Bioorganic Phosphorus Chemistry & Chemical Biology, Department of Chemistry, Tsinghua University, Beijing, 100084 P.R. China

E-mail: [email protected]; [email protected]; [email protected]; [email protected]

Search for more papers by this author
Xiaoyuan Chen

Corresponding Author

Xiaoyuan Chen

Department of Diagnostic Radiology, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, 119074 Singapore

Department of Chemical and Biomolecular Engineering, College of Design and Engineering, National University of Singapore, Singapore, 117575 Singapore

Department of Biomedical Engineering, College of Design and Engineering, National University of Singapore, Singapore, 117575 Singapore

Department of Pharmacy and Pharmaceutical Sciences, Faculty of Science, National University of Singapore, Singapore, 117544 Singapore

Clinical Imaging Research Centre, Centre for Translational Medicine, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, 117599 Singapore

Nanomedicine Translational Research Program, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, 117597 Singapore

Theranostics Center of Excellence (TCE), Yong Loo Lin School of Medicine, National University of Singapore, Singapore, 138667 Singapore

Institute of Molecular and Cell Biology, Agency for Science, Technology, and Research (A*STAR), Singapore, 138673 Singapore

E-mail: [email protected]; [email protected]; [email protected]; [email protected]

Search for more papers by this author
Sheng Wang

Corresponding Author

Sheng Wang

School of Life Sciences, Faculty of Medicine, Tianjin University, Tianjin, 300072 P.R. China

E-mail: [email protected]; [email protected]; [email protected]; [email protected]

Search for more papers by this author
First published: 10 June 2025

Graphical Abstract

To overcome the challenges of conventional proteolysis-targeting chimeras (PROTACs), various “unconventional PROTACs” including PROTACs with unconventional binding ligands, PROTACs with unconventional linkers, pro-PROTACs, and self-assembled PROTACs have been proposed. These unconventional PROTACs show great promise for targeted protein degradation in cancer therapy. This review summarizes recent advances in the development of unconventional PROTACs.

Abstract

Targeted protein degradation, which aims to eliminate dysregulated proteins, has emerged as a promising strategy for conquering challenging therapeutic targets. Proteolysis-targeting chimera (PROTAC) is a heterobifunctional molecule that utilizes the ubiquitin-proteasome system to selectively degrade target proteins. Due to its ability to degrade “undruggable” proteins without causing drug resistance, PROTAC has shown great potential in innovative drug development, especially in cancer therapy. However, conventional PROTACs suffer from several limitations, such as limited solubility, poor permeability, hook effect, and off-target toxicity. Therefore, structural innovation of conventional PROTACs to make them meet the therapeutic demand is essential for unlocking the full potential of PROTACs as a therapeutic tool. Here, we summarize four types of unconventional PROTACs for addressing the above challenges and enhancing cancer therapy efficacy, including PROTACs with unconventional binding ligands, PROTACs with unconventional linkers, pro-PROTACs, and self-assembled PROTACs. These optimized designs contribute to the development of PROTACs-based universal platforms, providing directions for innovative drug developments and expanding the applications of PROTACs in cancer therapy.

Conflict of Interests

The authors declare no conflict of interest.

Data Availability Statement

Data sharing is not applicable to this article as no new data were created or analyzed in this study.

The full text of this article hosted at iucr.org is unavailable due to technical difficulties.